Zhejiang Jolly Pharmaceutical Reports Record Cash Flow Amid Cost Reductions and Profit Growth

Zhejiang Jolly Pharmaceutical Co., Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment reflecting changes in its underlying metrics. The company reported notable financial results for the quarter ending March 2026, showcasing an operating cash flow of CNY 572.84 million, which stands as the highest recorded. Additionally, raw material costs have seen a reduction of 6.47% year-over-year, contributing positively to the overall financial landscape. The net sales for the same quarter reached CNY 897.8 million, marking a significant achievement for the company. With a return on equity (ROE) of 19.30%, Zhejiang Jolly Pharmaceutical presents an attractive valuation, supported by a price-to-book ratio of 2.76. Despite a return of -24.41% over the past year, the company has experienced a profit increase of 19.1%, and its PEG ratio is positioned at 0.8. Furthermore, the stock offers a dividend yield of 2.6%, adding to its appeal. This evaluation adjustment reflects the company's current standing in the market, emphasizing its financial performance and operational metrics. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.